Clinical trials: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Acute Demyelinating Syndrome, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial
Among all non viral encephalitis, myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD) are the second most frequent diagnosis in children.
- Trial name
- IDAR (NCT05545384)
- Testing
- Immediate Azathioprine (1st attack), Immediate Rituximab (1st attack), Standard of care
- Where
- 9 sites in France
- Volunteers
- 86 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis
Cohort Study on Neuroimmune Diseases in the Reproductive Age
Neuroimmune diseases are more prevalent among women of reproductive age. Studies have shown that neuroimmune diseases may impact fertility.
- Conditions
- Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis, Autoimmune Encephalitis, Myasthenia Gravis
- Trial name
- RANID (NCT07653984)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Neuromyelitis Optica Spectrum Disorders, MOGAD
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.
The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody associated disease (MOGAD) and in…
- Conditions
- Neuromyelitis Optica Spectrum Disorders, MOGAD, Multiple Sclerosis
- Trial name
- PoGe (NCT06865274)
- Testing
- Blood draw for the laboratory assessment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
MOGAD, Migraine
Headache Prevalence and Phenotype in Myelin Oligodendrocyte Glycoprotein Antibody -Associated Disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) is an inflammatory demyelinating disorder of the central nervous system characterized by antibodies targeting myelin oligodendrocyte glycoprotein (MOG).
- Conditions
- MOGAD, Migraine, Cephalalgia
- Trial name
- MOGHEAD (NCT07479212)
- Volunteers
- 25 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD).
- Trial name
- cosMOG (NCT05063162)
- Testing
- Rozanolixizumab
- Where
- 55 sites in United States, Australia and 18 more
- Volunteers
- 113 people
- Sponsor
- UCB Biopharma SRL
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
The purpose of the study is to evaluate the safety and efficacy of Tocilizumab in MOGAD.
- Trial name
- TOMATO (NCT06452537)
- Testing
- Tocilizumab, Prednisone
- Where
- 22 sites in China
- Volunteers
- 102 people
- Sponsor
- Tianjin Medical University General Hospital
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment…
- Trial name
- Meteoroid (NCT05271409)
- Testing
- Satralizumab
- Where
- 53 sites in United States, Australia and 9 more
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
NMO Spectrum Disorder, MRI
Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
CLUE is a prospective study to assess structural and functional changes of the brain, spinal cord, and optic nerve, as well as the inflammatory environment in patients with neuroinflammatory and demyelinating diseases.
- Conditions
- NMO Spectrum Disorder, MRI, Multiple Sclerosis, MOGAD
- Trial name
- NCT04106830
- Testing
- Intravenous steroid
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive…
- Conditions
- Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis
- Trial name
- CRSP-AID-502 (NCT07804004)
- Testing
- CTX112
- Volunteers
- 220 people
- Sponsor
- CRISPR Therapeutics
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging
The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy aging.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), Alzheimer Disease
- Trial name
- MESO7 (NCT07202494)
- Testing
- Imaging Techniques (MRI 3T & 7T, Functional, Structural, and Metabolic Imaging)
- Where
- France
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Antibody-mediated inflammatory diseases of the nervous system (also known as autoimmune diseases of the nervous system) are autoimmune diseases in which autoimmune cells and immune molecules attack the nervous system as the main…
- Conditions
- Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis
- Trial name
- CARTinNS (NCT04561557)
- Testing
- CT103A cells, Cyclophosphamide and fludarabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of QH103(Universal CD19 CAR-γδT Cell Injection)in the treatment of…
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Autoimmune Encephalitis (AE), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Trial name
- NCT07526493
- Testing
- Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Tongji Hospital
Central Nervous System Inflammation, MOG-IgG Associated Disease
Azathioprine in MOGAD
MOG-IgG associated disease (MOGAD) is a rare inflammatory disease of the central nervous system recently described. Initially reported as monophasic, data from incident cohorts suggests that around 50% of adult patients with…
- Trial name
- MOGwAI (NCT05349006)
- Testing
- Azathioprine
- Where
- 17 sites in France
- Volunteers
- 126 people
- Sponsor
- Hospices Civils de Lyon
Optic Neuritis, Transverse Myelitis
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland.
- Conditions
- Optic Neuritis, Transverse Myelitis, Acute Disseminated Encephalomyelitis, Multiple Sclerosis
- Trial name
- NCT05017142
- Where
- 13 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- University of Bern